HIPK2 is a new drug target for anti-fibrosis therapy in kidney disease

Melinda M. Nugent, Kyung Lee, John Cijiang He

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Abstract

In vitro and animal studies continue to elucidate the mechanisms of fibrosis and have led to advancements in treatment for idiopathic pulmonary fibrosis and cirrhosis, but the search for treatments for renal fibrosis has been more disappointing. Here, we will discuss homeodomain-interacting-protein kinase 2 (HIPK2), a novel regulator of fibrosis that acts upstream of major fibrosis signaling pathways. Its key role in renal fibrosis has been validated in vitro and in several murine models of chronic kidney diseases (CKD).

Original languageEnglish
Article number132
JournalFrontiers in Physiology
Volume6
Issue numberAPR
DOIs
StatePublished - 2015

Keywords

  • Fibrosis
  • HIPK2
  • Inflammation
  • Kidney
  • Signaling pathways

Fingerprint

Dive into the research topics of 'HIPK2 is a new drug target for anti-fibrosis therapy in kidney disease'. Together they form a unique fingerprint.

Cite this